Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges

Journal of Osteoporosis

Volumn 2016, Issue , 2016, Pages

  Macnabb, Claire ^a   Patton, D ^a   Hayes, J S ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMG 167; BLOSOZUMAB; BPS 804; DENOSUMAB; MONOCLONAL ANTIBODY; ODANACATIB; PARATHYROID HORMONE[1-34]; PLACEBO; ROMOSOZUMAB; SCLEROSTIN; SCLEROSTIN ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALVEOLAR BONE LOSS; AREA UNDER THE CURVE; ATRIAL FIBRILLATION; BONE MASS; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRACTURE FIXATION; FRACTURE HEALING; FRAGILITY FRACTURE; HEPATITIS; HUMAN; HYPOPHOSPHATASIA; IMMUNOGENICITY; INJECTION SITE REACTION; INTRAMEDULLARY NAILING; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONCARDIAC CHEST PAIN; NONHUMAN; ONCOCYTOMA; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHARMACODYNAMICS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SINGLE DRUG DOSE; TIBIA FRACTURE; UNSPECIFIED SIDE EFFECT; WRIST FRACTURE;

EID: 84975128740     PISSN: 20908059     EISSN: 20420064     Source Type: Journal    
DOI: 10.1155/2016/6217286     Document Type: Review

References (126)

1. E. M. Lewiecki, "Sclerostin monoclonal antibody therapy with AMG 785: A potential treatment for osteoporosis, " Expert Opinion on Biological Therapy, vol. 11, no. 1, pp. 117-127, 2011.
2. B. L. Clarke, "Anti-sclerostin antibodies: utility in treatment of osteoporosis, " Maturitas, vol. 78, no. 3, pp. 199-204, 2014.
3. L. Stodieck, AMGEN Countermeasures for Bone andMuscle Loss in Space and on Earth, 2013, http: //www. slideshare. net/astrosociety/ issrdc-2013-07170800stodieck.
4. D. Padhi, G. Jang, B. Stouch, L. Fang, and E. Posvar, "Singledose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody, " Journal of Bone and Mineral Research, vol. 26, no. 1, pp. 19-26, 2011.
5. Osteoporosis and Osteopenia, 2013, http: //decisionresources. com/Products-and-Services/Report?r=dbasmd0213.
6. B. C. Silva and J. P. Bilezikian, "Newapproaches tothe treatment of osteoporosis, " Annual Review of Medicine, vol. 62, pp. 307-322, 2011.
7. T. D. Rachner, S. Khosla, and L. C. Hofbauer, "Osteoporosis: now and the future, " The Lancet, vol. 377, no. 9773, pp. 1276-1287, 2011.
8. K. M. P. Akesson, "Capture the fracture: A global campaign to the fragility fracture cycle, " 2012, http: //www. iofbonehealth. org/ capture-fracture-report-2012.
9. O. Johnell, "The socioeconomic burden of fractures: today and in the 21st century, " The American Journal of Medicine, vol. 103, no. 2, supplement 1, pp. S20-S26, 1997.
10. G. Marongiu, M. Mastio, and A. Capone, "Current options to surgical treatment in osteoporotic fractures, " Aging Clinical and Experimental Research, vol. 25, supplement 1, pp. S15-S17, 2013.
11. S. C. Mears, "Management of severe osteoporosis in primary total hip arthroplasty, " Current Translational Geriatrics and ExperimentalGerontology Reports, vol. 2, no. 2, pp. 99-104, 2013.
12. E. Hernlund, A. Svedbom, M. IverGard et al., "Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the InternationalOsteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA), " Archives of Osteoporosis, vol. 8, no. 1-2, article 136, 2013.
13. B. L. Riggs and L. J. Melton III, "The worldwide problem of osteoporosis: insights afforded by epidemiology, " Bone, vol. 17, no. 5, supplement 1, pp. S505-S511, 1995.
14. H. Hamersma, J. Gardner, and P. Beighton, "The natural history of sclerosteosis, " Clinical Genetics, vol. 63, no. 3, pp. 192-197, 2003.
15. A. G. Costa and J. P. Bilezikian, "Sclerostin: therapeutichorizons basedupon its actions, " CurrentOsteoporosis Reports, vol. 10, no. 1, pp. 64-72, 2012.
16. W. Balemans, M. Ebeling, N. Patel et al., "Increasedbonedensity in sclerosteosis is due to the deficiency of a novel secreted protein (SOST), " Human Molecular Genetics, vol. 10, no. 5, pp. 537-543, 2001.
17. M. E. Brunkow, J. C. Gardner, J. Van Ness et al., "Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein, " The American Journal of Human Genetics, vol. 68, no. 3, pp. 577-589, 2001.
18. D. G. Winkler, M. K. Sutherland, J. C. Geoghegan et al., "Osteocyte control of bone formation via sclerostin, a novel BMP antagonist, " The EMBO Journal, vol. 22, no. 23, pp. 6267-6276, 2003.
19. C. Krause, O. Korchynskyi, K. de Rooij et al., "Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways, "The Journal of Biological Chemistry, vol. 285, no. 53, pp. 41614-41626, 2010.
20. A. R. Wijenayaka, M. Kogawa, H. P. Lim, L. F. Bonewald, D. M. Findlay, and G. J. Atkins, "Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway, " PLoS ONE, vol. 6, no. 10, Article ID e25900, 2011.
21. R. R. Recker, C. T. Benson, T. Matsumoto et al., "A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density, " Journal of Bone and Mineral Research, vol. 30, no. 2, pp. 216-224, 2015.
22. X. Li, Y. Zhang, H. Kang et al., "Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling, " The Journal of Biological Chemistry, vol. 280, no. 20, pp. 19883-19887, 2005.
23. M. V. Semenov and X. He, "LRP5mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST, "The Journal of Biological Chemistry, vol. 281, no. 50, pp. 38276-38284, 2006.
24. R. Sugimura and L. Li, "Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases, " Birth Defects Research Part C: Embryo Today: Reviews, vol. 90, no. 4, pp. 243-256, 2010.
25. M. L. Johnson and M. A. Kamel, "The Wnt signaling pathway and bone metabolism, " Current Opinion in Rheumatology, vol. 19, no. 4, pp. 376-382, 2007.
26. R. Baron and M. Kneissel, "WNTsignaling in bone homeostasis and disease: from human mutations to treatments, " Nature Medicine, vol. 19, no. 2, pp. 179-192, 2013.
27. V. Krishnan, H. U. Bryant, and O. A. MacDougald, "Regulation of bone mass by Wnt signaling, "The Journal of Clinical Investigation, vol. 116, no. 5, pp. 1202-1209, 2006.
28. T. F. Day, X. Guo, L. Garrett-Beal, and Y. Yang, "Wnt/-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis, " Developmental Cell, vol. 8, no. 5, pp. 739-750, 2005.
29. D. A. Glass II, P. Bialek, J. D. Ahn et al., "Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation, " Developmental Cell, vol. 8, no. 5, pp. 751-764, 2005.
30. W. Qiu, L. Chen, and M. Kassem, "Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells, " Biochemical and Biophysical Research Communications, vol. 413, no. 1, pp. 98-104, 2011.
31. K. Maeda, N. Takahashi, and Y. Kobayashi, "Roles of Wnt signals in bone resorption during physiological and pathological states, " Journal of Molecular Medicine, vol. 91, no. 1, pp. 15-23, 2013.
32. H. Z. Ke, W. G. Richards, X. Li, and M. S. Ominsky, "Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases, " Endocrine Reviews, vol. 33, no. 5, pp. 747-783, 2012.
33. Y. Gong, R. B. Slee, N. Fukai et al., "LDL receptor-relatedprotein 5 (LRP5) affects bone accrual and eye development, " Cell, vol. 107, no. 4, pp. 513-523, 2001.
34. M. L. Johnson, G. Gong, W. Kimberling, S. M. Recker, D. B. Kimmel, and R. R. Recker, "Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13), " American Journal of Human Genetics, vol. 60, no. 6, pp. 1326-1332, 1997.
35. R. D. Little, C. Folz, S. P. Manning et al., "Amutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait, " The American Journal of Human Genetics, vol. 70, no. 1, pp. 11-19, 2002.
36. M. Kato, M. S. Patel, R. Levasseur et al., "Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, aWnt coreceptor, " Journal of Cell Biology, vol. 157, no. 2, pp. 303-314, 2002.
37. P. Babij, W. Zhao, C. Small et al., "High bone mass in mice expressing a mutant LRP5 gene, " Journal of Bone and Mineral Research, vol. 18, no. 6, pp. 960-974, 2003.
38. W. Wei, D. Zeve, J. M. Suh et al., "Biphasic and dosage-dependent regulation of osteoclastogenesis by-catenin, " Molecular and Cellular Biology, vol. 31, no. 23, pp. 4706-4719, 2011.
39. T. P. Hill, D. Später, M. M. Taketo, W. Birchmeier, and C. Hartmann, "Canonical Wnt/-catenin signaling prevents osteoblasts from differentiating into chondrocytes, " Developmental Cell, vol. 8, no. 5, pp. 727-738, 2005.
40. S. L. Holmen, C. R. Zylstra, A. Mukherjee et al., "Essential roleof-catenin in postnatal bone acquisition, " The Journal of Biological Chemistry, vol. 280, no. 22, pp. 21162-21168, 2005.
41. I. Kramer, C. Halleux, H. Keller et al., "OsteocyteWnt/-catenin signaling is required for normal bone homeostasis, " Molecular and Cellular Biology, vol. 30, no. 12, pp. 3071-3085, 2010.
42. J. Albers, J. Keller, A. Baranowsky et al., "CanonicalWnt signaling inhibits osteoclastogenesis independent of osteoprotegerin, " The Journal of Cell Biology, vol. 200, no. 4, pp. 537-549, 2013.
43. T. A. Yorgan, S. Peters, A. Jeschke et al., "The anti-osteoanabolic function of sclerostin is blunted in mice carrying a high bone mass mutation of Lrp5, " Journal of Bone and Mineral Research, vol. 30, no. 7, pp. 1175-1183, 2015.
44. X. Li, M. S. Ominsky, Q.-T. Niu et al., "Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength, " Journal of Bone and Mineral Research, vol. 23, no. 6, pp. 860-869, 2008.
45. G. J. Atkins, P. S. Rowe, H. P. Lim et al., "Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through aMEPE-ASARMdependent mechanism, " Journal of Bone and Mineral Research, vol. 26, no. 7, pp. 1425-1436, 2011.
46. P. Nioi, S. Taylor, R. Hu et al., "Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats, " Journal of Bone andMineral Research, vol. 30, no. 8, pp. 1457-1467, 2015.
47. M. K. Robinson, J. Caminis, and M. E. Brunkow, "Sclerostin: how humanmutations have helped reveal a new target for the treatment of osteoporosis, " Drug Discovery Today, vol. 18, no. 13-14, pp. 637-643, 2013.
48. M. J. C. Moester, S. E. Papapoulos, C. W. G. M. Löwik, and R. L. van Bezooijen, "Sclerostin: current knowledge and future perspectives, " Calcified Tissue International, vol. 87, no. 2, pp. 99-107, 2010.
49. E. M. Lewiecki, "Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases, " Therapeutic Advances in Musculoskeletal Disease, vol. 6, no. 2, pp. 48-57, 2014.
50. X. Li, M. S. Ominsky, K. S. Warmington et al., "Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis, " Journal of Bone andMineral Research, vol. 24, no. 4, pp. 578-588, 2009.
51. R. D. Ross, L. H. Edwards, A. S. Acerbo et al., "Bone matrix quality after sclerostin antibody treatment, " Journal of Bone and Mineral Research, vol. 29, no. 7, pp. 1597-1607, 2014.
52. M. S. Ominsky, F. Vlasseros, J. Jolette et al., "Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength, " Journal of Bone and Mineral Research, vol. 25, no. 5, pp. 948-959, 2010.
53. D. Padhi, M. Allison, A. J. Kivitz et al., "Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal womenwith lowbone mass: A randomized, doubleblind, placebo-controlled study, " Journal of Clinical Pharmacology, vol. 54, no. 2, pp. 168-178, 2014.
54. M. R. McClung, J. SanMartin, P. D. Miller et al., "Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass, " Archives of Internal Medicine, vol. 165, no. 15, pp. 1762-1768, 2005.
55. M. R. McClung, A. Grauer, S. Boonen et al., "Romosozumab in postmenopausal women with low bone mineral density, " The New England Journal of Medicine, vol. 370, no. 5, pp. 412-420, 2014.
56. M. R. McClung, A. Chines, J. P. Brown et al., "OP0251 effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density, " Annals of the Rheumatic Diseases, vol. 74, supplement 2, pp. 166-167, 2015.
57. J. McColm, L. Hu, T. Womack, C. C. Tang, and A. Y. Chiang, "Single-and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women, " Journal of Bone andMineral Research, vol. 29, no. 4, pp. 935-943, 2014.
58. C. P. Recknor, R. R. Recker, C. T. Benson et al., "The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density, " Journal of Bone and Mineral Research, vol. 30, no. 9, pp. 1717-1725, 2015.
59. Novartis, Novartis Clinical Innovations Pipeline Annual Report, Pharmaceuticals, 2014.
60. A. Morse, M. M. McDonald, N. H. Kelly et al., "Mechanical load increases in bone formation via a sclerostin-independent pathway, " Journal of Bone and Mineral Research, vol. 29, no. 1, pp. 2456-2467, 2014.
61. M.-K. Chang, I. Kramer, H. Keller et al., "Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity, " Journal of Bone and Mineral Research, vol. 29, no. 1, pp. 29-42, 2014.
62. A. Morse, N. Y. C. Yu, L. Peacock et al., "Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength, " Bone, vol. 71, pp. 155-163, 2015.
63. X. Li, M. S. Ominsky, K. S. Warmington et al., "Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats, " Endocrinology, vol. 152, no. 9, pp. 3312-3322, 2011.
64. J. S. Finkelstein, A. Hayes, J. L. Hunzelman, J. J. Wyland, H. Lee, and R. M. Neer, "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, " The New England Journal of Medicine, vol. 349, no. 13, pp. 1216-1226, 2003.
65. J. S. Finkelstein, B. Z. Leder, S.-A. M. Burnett et al., "Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men, " The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 8, pp. 2882-2887, 2006.
66. L. Cui, H. Cheng, C. Song et al., "Time-dependent effects of sclerostin antibody on a mouse fracture healing model, " Journal of Musculoskeletal & Neuronal Interactions, vol. 13, no. 2, pp. 178-184, 2013.
67. P. K. Suen, Y.-X. He, D. H. K. Chow et al., "Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats, " Journal of Orthopaedic Research, vol. 32, no. 8, pp. 997-1005, 2014.
68. M. S. Ominsky, C. Li, X. Li et al., "Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones, " Journal of Bone and Mineral Research, vol. 26, no. 5, pp. 1012-1021, 2011.
69. M. M. McDonald, A. Morse, K. Mikulec et al., "Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats, " Journal of Orthopaedic Research, vol. 30, no. 10, pp. 1541-1548, 2012.
70. M. U. Jawad, K. E. Fritton, T. Ma et al., "Effects of sclerostin antibody on healing of a non-critical size femoral bone defect, " Journal of Orthopaedic Research, vol. 31, no. 1, pp. 155-163, 2013.
71. C. S. Yee, L. Xie, S. Hatsell et al., "Sclerostin antibody treatment improves fracture outcomes in a type i diabetic mouse model, " Bone, vol. 82, pp. 122-134, 2016.
72. M. S. Virk, F. Alaee, H. Tang, M. S. Ominsky, H. Z. Ke, and J. R. Lieberman, "Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model, "The Journal of Bone&Joint Surgery-American Volume, vol. 95, no. 8, pp. 694-701, 2013.
73. F. Alaee, M. S. Virk, H. Tang et al., "Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model, " Journal of Orthopaedic Research, vol. 32, no. 2, pp. 197-203, 2014.
74. J. Levin, Acceleration of FractureHealingwithCDP7851/AMG785 Will Not Move into Phase 3, FierceBiotech, 2013, http: //www. fiercebiotech. com/press-releases/acceleration-fracture-healingcdp7851amg785-will-not-move-phase-3.
75. K. Sarahrudi, A. Thomas, C. Albrecht, and S. Aharinejad, "Strongly enhanced levels of sclerostin during human fracture healing, " Journal of Orthopaedic Research, vol. 30, no. 10, pp. 1549-1555, 2012.
76. F. Agholme, X. Li, H. Isaksson, H. Z. Ke, and P. Aspenberg, "Sclerostin antibody treatment enhances metaphyseal bone healing in rats, " Journal of Bone and Mineral Research, vol. 25, no. 11, pp. 2412-2418, 2010.
77. A. S. Virdi, M. Liu, K. Sena et al., "Sclerostin antibody increases bone volume and enhances implant fixation in a rat model, " The Journal of Bone & Joint Surgery-American Volume, vol. 94, no. 18, pp. 1670-1680, 2012.
78. S. Liu, A. S. Virdi, K. Sena, and D. R. Sumner, "Sclerostin antibody prevents particle-induced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model, " Arthritis and Rheumatism, vol. 64, no. 12, pp. 4012-4020, 2012.
79. A. S. Virdi, J. Irish, K. Sena et al., "Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis, " The Journal of Bone & Joint Surgery-AmericanVolume, vol. 97, no. 2, pp. 133-140, 2015.
80. A. Eddleston, M. Marenzana, A. R. Moore et al., "A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis, " Journal of Bone and Mineral Research, vol. 24, no. 10, pp. 1662-1671, 2009.
81. X.-X. Chen, W. Baum, D. Dwyer et al., "Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis, " Annals of the Rheumatic Diseases, vol. 72, no. 10, pp. 1732-1736, 2013.
82. C. Hamann, M. Rauner, Y. Höhna et al., "Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus, " Journal of Bone and Mineral Research, vol. 28, no. 3, pp. 627-638, 2013.
83. B. P. Sinder, M. M. Eddy, M. S. Ominsky, M. S. Caird, J. C. Marini, and K. M. Kozloff, "Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta, " Journal of Bone and Mineral Research, vol. 28, no. 1, pp. 73-80, 2013.
84. A. G. Costa, J. P. Bilezikian, and E. M. Lewiecki, "The potential use of antisclerostin therapy in chronic kidney disease- mineral and bone disorder, " Current Opinion in Nephrology and Hypertension, vol. 24, no. 4, pp. 324-329, 2015.
85. Y. Ren, X. Han, S. P. Ho et al., "Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model, " FASEB Journal, vol. 29, no. 7, pp. 2702-2711, 2015.
86. A. Roschger, P. Roschger, P. Keplingter et al., "Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta, " Bone, vol. 66, pp. 182-188, 2014.
87. D. Gatti, F. Antoniazzi, R. Prizzi et al., "Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study, " Journal of Bone andMineral Research, vol. 20, no. 5, pp. 758-763, 2005.
88. R. Sakkers, D. Kok, R. Engelbert et al., "Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study, " The Lancet, vol. 363, no. 9419, pp. 1427-1431, 2004.
89. M. P. Whyte, W. H. McAlister, D. V. Novack, K. L. Clements, P. L. Schoenecker, and D. Wenkert, "Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases, " Journal of Bone and Mineral Research, vol. 23, no. 10, pp. 1698-1707, 2008.
90. L. M. Ward, F. Rauch, M. P. Whyte et al., "Alendronate for the treatment of pediatric osteogenesis imperfecta: A randomized placebo-controlled study, " Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 355-364, 2011.
91. F. Rauch, C. F. Munns, C. Land, M. Cheung, and F. H. Glorieux, "Risedronate in the treatment of mild pediatric osteogenesis imperfecta: A randomized placebo-controlled study, " Journal of Bone and Mineral Research, vol. 24, no. 7, pp. 1282-1289, 2009.
92. A. D. Letocha, H. L. Cintas, J. F. Troendle et al., "Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement, " Journal of Bone andMineral Research, vol. 20, no. 6, pp. 977-986, 2005.
93. J. L. Vahle, M. Sato, G. G. Long et al., "Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety, " Toxicologic Pathology, vol. 30, no. 3, pp. 312-321, 2002.
94. J. C. Marini, E. Hopkins, F. H. Glorieux et al., "Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen, " Journal of Bone and Mineral Research, vol. 18, no. 2, pp. 237-243, 2003.
95. M. Roudier, X. Li, Q.-T. Niu et al., "Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury, " Arthritis and Rheumatism, vol. 65, no. 3, pp. 721-731, 2013.
96. M. H. Napimoga, C. Nametala, F. L. Da Silva et al., "Involvement of the Wnt-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis, " Journal of Clinical Periodontology, vol. 41, no. 6, pp. 550-557, 2014.
97. U. Kuchler, U. Y. Schwarze, T. Dobsak et al., "Dental and periodontal phenotype in sclerostin knockout mice, " International Journal of Oral Science, vol. 6, no. 2, pp. 70-76, 2014.
98. P. Han, S. Ivanovski, R. Crawford, and Y. Xiao, "Activation of the canonical Wnt signaling pathway induces cementum regeneration, " Journal of Bone andMineral Research, vol. 30, no. 7, pp. 1160-1174, 2015.
99. A. D. Taut, Q. Jin, J.-H. Chung et al., "Sclerostin antibody stimulates bone regeneration after experimental periodontitis, " Journal of Bone and Mineral Research, vol. 28, no. 11, pp. 2347-2356, 2013.
100. H. Chen, X. Xu, M. Liu et al., "Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis, " Bone, vol. 76, pp. 141-148, 2015.
101. K. G. Murphy and J. C. Gunsolley, "Guided tissue regeneration for the treatment of periodontal intrabony and furcation defects. A systematic review, " Annals of Periodontology, vol. 8, no. 1, pp. 266-302, 2003.
102. S. Ivanovski, C. Vaquette, S. Gronthos, D. W. Hutmacher, and P. M. Bartold, "Multiphasic scaffolds for periodontal tissue engineering, " Journal ofDental Research, vol. 93, no. 12, pp. 1212-1221, 2014.
103. S. Pelletier, L. Dubourg, M.-C. Carlier, A. Hadj-Aissa, and D. Fouque, "The relation between renal function and serum sclerostin in adult patients with CKD, " Clinical Journal of the American Society of Nephrology, vol. 8, no. 5, pp. 819-823, 2013.
104. M. Kanbay, D. Siriopol, M. Saglam et al., "Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients, " Journal of Clinical Endocrinology andMetabolism, vol. 99, no. 10, pp. E1854-E1861, 2014.
105. V. M. Brandenburg, R. Kramann, R. Koos et al., "Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: A cross-sectional study, " BMC Nephrology, vol. 14, article 219, 2013.
106. R. Kramann, V. M. Brandenburg, L. J. Schurgers et al., "Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy, " NephrologyDialysis Transplantation, vol. 28, no. 4, pp. 856-868, 2013.
107. L. J. Schurgers, E. C. M. Cranenburg, and C. Vermeer, "Matrix Gla-protein: the calcification inhibitor in need of vitamin K, " Thrombosis and Haemostasis, vol. 100, no. 4, pp. 593-603, 2008.
108. M. Hayashi, I. Takamatsu, Y. Kanno, T. Yoshida, T. Abe, and Y. Sato, "A case-control study of calciphylaxis in Japanese endstage renal disease patients, " Nephrology Dialysis Transplantation, vol. 27, no. 4, pp. 1580-1584, 2012.
109. R. L. van Bezooijen, S. E. Papapoulos, and C. W. Löwik, "Bone morphogenetic proteins and their antagonists: the sclerostin paradigm, " Journal of Endocrinological Investigation, vol. 28, no. 8, supplement, pp. 15-17, 2005.
110. L. Desjardins, S. Liabeuf, R. B. Oliveira et al., "Uremic toxicity and sclerostin in chronic kidney disease patients, " Nephrologie & therapeutique, vol. 10, no. 6, pp. 463-470, 2014.
111. L. Viaene, G. J. Behets, K. Claes et al., "Sclerostin: Another bonerelated protein related to all-causemortality in haemodialysis" Nephrology Dialysis Transplantation, vol. 28, no. 12, pp. 3024-3030, 2013.
112. C. Drechsler, P. Evenepoel, M. G. Vervloet et al., "High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study, " Nephrology Dialysis Transplantation, vol. 30, no. 2, pp. 288-293, 2015.
113. S. M. Moe, N. X. Chen, C. L. Newman et al., "Anti-sclerostin antibody treatment in a ratmodel of progressive renal osteodystrophy, " Journal of Bone andMineral Research, vol. 30, no. 3, pp. 499-509, 2015.
114. C. L. Newman, N. X. Chen, E. Smith et al., "Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions, " Bone, vol. 77, pp. 50-56, 2015.
115. V. Boschert, E.-M. Muth, A. Knappik, C. Frisch, and T. D. Mueller, "Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097, " Acta Crystallographica Section F: Structural Biology Communications, vol. 71, part 4, pp. 388-392, 2015.
116. Q. Yao, J. Ni, Y. Hou, L. Ding, L. Zhang, and H. Jiang, "Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats, " Cell Biochemistry and Biophysics, vol. 69, no. 2, pp. 229-235, 2014.
117. L. A. Johnson, Amgen, UCB Halt Testing of Drug for Fracture Healing, But Continue Testing for Osteoporosis, Associated Press, 2013, http: //news. yahoo. com/amgen-ucb-halt-testing-fracture-203100125. html.
118. J. C. Gardner, R. L. van Bezooijen, B. Mervis et al., "Bone mineral density in sclerosteosis; affected individuals and gene carriers, " The Journal of Clinical Endocrinology andMetabolism, vol. 90, no. 12, pp. 6392-6395, 2005.
119. R. T. Moon, A. D. Kohn, G. V. De Ferrari, and A. Kaykas, "WNT and-catenin signalling: diseases and therapies, " Nature Reviews Genetics, vol. 5, no. 9, pp. 691-701, 2004.
120. H. Clevers and R. Nusse, "Wnt/-catenin signaling and disease, " Cell, vol. 149, no. 6, pp. 1192-1205, 2012.
121. M. Kahn, "Can we safely target the WNT pathwaY" Nature Reviews Drug Discovery, vol. 13, no. 7, pp. 513-532, 2014.
122. M. Jia, S. Chen, B. Zhang et al., "Effects of constitutive-catenin activation on vertebral bone growth and remodeling at different postnatal stages in mice, " PLoS ONE, vol. 8, no. 9, Article ID e74093, 2013.
123. S. Chen, J. Feng, Q. Bao et al., "Adverse effects of osteocytic constitutive activation of ß-catenin on bone strength and bone growth, " Journal of Bone andMineral Research, vol. 30, no. 7, pp. 1184-1194, 2015.
124. R. BaronandE. Hesse, "Updateonbone anabolics inosteoporosis treatment: rationale, current status, and perspectives, " The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 311-325, 2012.
125. M. Stolina, D. Dwyer, Q.-T. Niu et al., "Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats, " Bone, vol. 67, pp. 305-313, 2014.
126. M. Co, MerckAnnounces Data from Pivotal Phase 3 FractureOutcomes Study forOdanacatib, an InvestigationalOral, Once-Weekly Treatment for Osteoporosis, 2014, http: //www. mercknewsroom. com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st.